ZT-01 not checked

Zucara Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days”In the company’s words, NCT05762107 on ClinicalTrials.gov
Tested for
Type 1 Diabetes Mellitus With Hypoglycemia
Main trialPhase 2
“The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars ("hypos") at night. ZT-01 increases the amount of a hormone called glucagon during low blood sugar, and this may help prevent the occurrence of hypos. The main questions this trial aims to answer are whether ZT-01 lowers the number of hypos happening at night, and what its effects are on blood sugar levels. The safety of ZT-01 will also be measured. Participants will be asked to wear a…”In the company’s words, NCT05762107 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Dec 2026 A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Phase 1Terminated 12 Apr 2022 Effect of ZT-01 on Glucagon During Hypoglycemia in Type 1 Diabetes Mellitus
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ZT-01

Following is part of Solo: you see every change to ZT-01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in